Document:

<Page>

                                                                    EXHIBIT 10.1

                                   L-99-1261

                                LICENSE AGREEMENT

                                       FOR

                                    DETECTOR

                                     BETWEEN

                               DIGIRAD CORPORATION

                                       AND

                   THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

                                   THROUGH THE

                             ERNEST ORLANDO LAWRENCE
                          BERKELEY NATIONAL LABORATORY

<Page>

                                   L-99-1261

                                TABLE OF CONTENTS

1.   BACKGROUND                                                           1

2.   DEFINITIONS                                                          1

3.   LICENSE GRANT                                                        3

4.   LICENSE ISSUE FEE                                                    4

5.   ROYALTIES AND PAYMENTS                                               4

6    PERFORMANCE REQUIREMENTS                                             6

7    PROGRESS AND ROYALTY REPORTS                                         7

8.   BOOKS AND RECORDS                                                    8

9.   LIFE OF THE AGREEMENT                                                8

10.  TERMINATION BY BERKELEY LAB                                          9

11.  TERMINATION BY DIGIRAD                                               9

12.  DISPOSITION OF LICENSED PRODUCTS                                     9

13.  USE OF NAMES AND TRADEMARKS AND NONDISCLOSURE OF AGREEMENT           9

14.  LIMITED WARRANTY                                                    10

15.  PATENT PROSECUTION AND MAINTENANCE                                  11

16.  PATENT INFRINGEMENT                                                 13

17   WAIVER                                                              13

18.  ASSIGNMENT                                                          13

19.  INDEMNIFICATION                                                     13

20.  LATE PAYMENTS                                                       15

<Page>

                                   L-99-1261

21.  NOTICES                                                             15

22.  U.S.  MANUFACTURE                                                   15

23.  PATENT MARKING                                                      16

24.  GOVERNMENT APPROVAL OR REGISTRATION                                 16

25.  EXPORT CONTROL LAWS                                                 16

26.  FORCE MAJEURE                                                       16

27   MISCELLANEOUS                                                       16

<Page>

                                                                       L-99-1261

                         LICENSE AGREEMENT FOR DETECTOR

This license agreement (the "Agreement") is entered into by The Regents of the
University of California ("The Regents"), Department of Energy
contract-operators of the Ernest Orlando Lawrence Berkeley National Laboratory,
1 Cyclotron Road, Berkeley, CA 94720, (jointly, "Berkeley Lab"), and Digirad
Corporation, ("Digirad") a Delaware corporation, having as its principle place
of business, 9350 Trade Place San Diego, California 92126-6330.

                                  1. BACKGROUND

1.1      A certain invention, ***
                              ***
         (the "Invention"), was made under U.S. Department of Energy contract
         ***
         *** at the University of California, Ernest Orlando Lawrence Berkeley
         National Laboratory by Steven Edward Holland.

1.2      As DOE sponsored development of the Invention, this Agreement and the
         resulting license are subject to overriding obligations to the federal
         government pursuant to the provisions of the applicable law or
         regulations.

1.3      Berkeley Lab wants the Invention developed and used to the fullest
         extent so that the general public enjoys the benefits of the
         government-sponsored research.

1.4      Digirad wants to obtain certain rights from Berkeley Lab for the
         commercial development, manufacture, use, and sale of the Invention.

1.5      Digirad entered into an Option Agreement with Berkeley Lab to license
         the above referenced invention on June 3, 1998.

1.6      Digirad is a "small business firm" as defined at Section 2 of Public
         Law 85-536 (15 U.S.C. 632).

Therefore the parties agree as follows:

                                 2. DEFINITIONS

2.1      "Effective Date" means the date of execution by the last signing party.

2.2      "Field of Use" means the development, production and use ***
                                             ***
                                             ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    1 of 17
<Page>

                                                                       L-99-1261

2.3      "Highly Inflationary Currency" means the currency of any economy with a
         cumulative inflation rate of *** or more over the most recent *** , as
         measured by consumer price indices published by the ***
         ***

2.4      "Licensed Patents" means patent rights to any subject matter claimed in
         or covered by
                                                     ***
                                                     ***
         *** or any corresponding foreign patent application or patent, for
         which Digirad has met the requirements of Section 15.2 herein; any
         division, reexamination, continuation, continuation-in-part (excluding
         new matter contained and claimed in that continuation-in-part), or of
         which such application is a successor; any patents issuing on any of
         the foregoing, and all renewals, reissues and extensions thereof, or
         other equivalents of a renewal, reissues and extension thereof.

2.5      "Licensed Product" means any product, service or process that employs
         or is produced by the practice of any invention claimed in Licensed
         Patents and whose manufacture, use, practice, sale, or lease would
         constitute, but for the license Berkeley Lab grants to Digirad under
         this Agreement, an infringement of any claim in Licensed Patents.

2.6      "Selling Price" for the purpose of computing royalties means the price
         at which Digirad or its sublicensee sells the Licensed Product in an
         arms-length transaction, less the sum of the following deductions that
         are customary and actually taken: ***
                                                     ***
                                                     ***
                                                     ***
         When a Licensed Product is not sold, but is otherwise disposed of, the
         Selling Price of that Licensed Product for the purposes of computing
         royalties is ***
                                                     ***
         *** When such products are not currently being offered for sale by
         Digirad, the Selling Price of a Licensed Product otherwise disposed of,
         for the purpose of computing royalties, is ***
                                                     ***
         *** When such products are not currently sold or offered for sale by
         Digirad or others, then the Selling Price, for the purpose of computing
         royalties, shall be
                                            ***
         *** For sales of Licensed Products to a Joint Venture or Affiliate (as
         defined in Paragraphs 2.7 and 2.8 below) that are provided by Digirad
         to the Joint Venture or Affiliate (directly or indirectly for resale by
         said Joint Venture or Affiliate) at a reduced price from that
         customarily charged to an unrelated third party, then the royalty paid
         to Berkeley Lab will be based on ***
                                                     ***
         *** For sales of Licensed Products to a Joint

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    2 of 17
<Page>

                                                                       L-99-1261

         Venture or Affiliate (as defined in Paragraphs 2.7 and 2.8 below) that
         are provided directly or indirectly by Digirad to the Joint Venture or
         Affiliate as an end user at a reduced price from that customarily
         charged to an unrelated third party, then the royalty paid to Berkeley
         Lab will be based on *** ***

2.7      "Affiliate(s)" of a party means                      ***
                                                     ***
                                                     ***
                                                     ***

2.8      "Joint Venture" means any separate entity established pursuant to an
         agreement between a third party and Digirad to constitute a vehicle for
         a joint venture, which separate entity purchases, sells or acquires
         Licensed Products from Digirad at prices substantially different from
         those at which Digirad would have charged other purchasers that deal at
         arms length with Digirad. If such separate entity is established, then
         Berkeley Lab shall collect from Digirad royalties on the Selling Price
         of Licensed Products by the entity and shall not collect royalties on
         the Selling Price of Licensed Products by Digirad.

                                3. LICENSE GRANT

3.1      Subject to the limitations set forth in this Agreement, Berkeley Lab
         grants to Digirad a nontransferable (subject to Section 18.1), limited
         (by the terms of Sections 3.2 and 3.7) worldwide exclusive,
         royalty-bearing license, under Licensed Patents, only in the Field of
         Use, to develop, make, have made, use, practice, sell, have sold, and
         lease the Licensed Products.

3.2      Any license under this Agreement is subject to the following: (a) DOE's
         royalty-free license for federal government practice only, and (b)
         DOE's option to grant licenses either if reasonable steps to
         commercialize the Invention are not carried out or in order to meet
         federal regulations. Digirad shall use best efforts to commercialize
         Licensed Patents.

3.3      Berkeley Lab also grants to Digirad the right to issue royalty-bearing
         sublicenses only in the Field of Use to make, use, practice and sell
         Licensed Products, so long as Digirad has current exclusive rights in
         the Field of Use.

3.4      Any sublicense Digirad grants must be consistent with all the rights
         and obligations due Berkeley Lab and the United States Government under
         this Agreement, including, without limitation, the obligations under
         Section 3.2 above.

3.5      Digirad shall provide Berkeley Lab with a copy of each sublicense
         issued under this Agreement; collect payment of all royalties due
         Berkeley Lab from sublicensees; and summarize and deliver all reports
         due Berkeley Lab from sublicensees under Article 7 (PROGRESS AND
         ROYALTY REPORTS).

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    3 of 17
<Page>

                                                                       L-99-1261

3.6      If this Agreement terminates for any reason,  ***
                                                     ***

3.7      Berkeley Lab expressly reserves the right to use the Invention and
         associated technology for educational and research purposes subject to
         the limitations of Section 13.2.

                              4. LICENSE ISSUE FEE

4.1      Digirad shall pay Berkeley Lab a license issue fee of ***
                                                     ***
                                                     ***
                                                     ***
                                                     ***
                           ***

4.2      This fee is                        ***

                            5. ROYALTIES AND PAYMENTS

5.1        Digirad shall pay to Berkeley Lab an earned royalty ***
         *** of the Selling Price of each Licensed Product Digirad sells.

5.2      Under this Agreement a Licensed Product is considered to be sold when
         invoiced, or if not invoiced, when delivered to a third party. But when
         the last patent covering a Licensed Product expires or when the license
         terminates, any shipment made on or before the day of that expiration
         or termination that has not been billed out before is considered as
         sold (and therefore subject to royalty) unless returned to Digirad
         within *** . Berkeley Lab shall credit royalties that Digirad pays on a
         Licensed Product that the customer does not accept or returns.

5.3      For each sublicense, Digirad shall pay Berkeley Lab  ***
                                            ***
                                            ***
                                            ***
                                            ***
                           ***

5.4      Digirad shall pay to Berkeley Lab by *** of each year the difference
         between the earned royalties for that calendar year Digirad has already
         paid to Berkeley Lab and the minimum annual royalty set forth in the
         following schedule. Berkeley Lab shall credit that minimum annual
         royalty paid against the earned royalty due and owing for the calendar
         year in which Digirad made the minimum payment

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    4 of 17
<Page>

                                                                       L-99-1261

<Table>
<Caption>
              CALENDAR YEAR                            MINIMUM ANNUAL ROYALTY
              -------------                            ----------------------
              <S>                                      <C>
                  1999                                 $ ***
                  2000                                 $ ***
                  2001                                 $ ***
                  2002 and each year thereafter        $ ***
</Table>

5.5      Digirad shall send payment for royalties accruing to Berkeley Lab ***
         together with its royalty report under paragraph 7.4. Digirad shall be
         entitled to credit ***
                                                     ***
                                                     ***
                           ***

5.6      Digirad shall make checks payable to "The Regents of the University of
         California (Berkeley Lab/L-99-1261.)" Digirad shall pay Berkeley Lab
         only in United States dollars. If a Licensed Product is sold for moneys
         other than United States dollars (not including Highly Inflationary
         Currency), Digirad shall ***
                                                     ***
                                                     ***
                                                     ***
         If a Licensed Product is sold for a Highly Inflationary Currency,
         Digirad shall ***
                                                     ***
                                                     ***
                                                     ***
                  ***

5.7      Digirad may not reduce royalties payable by  ***
                                                     ***
                                                     ***
                  ***

5.8      If Digirad cannot promptly remit any royalties for sales in any country
         where a Licensed Product is sold because of legal restrictions, Digirad
         may deposit in United States funds royalties due Berkeley Lab to
         Berkeley Lab's account in a bank or other depository in that country.
         If Digirad is not permitted to deposit those payments in U.S. funds
         under the laws of that country, Digirad may deposit those payments in
         the local currency to Berkeley Lab's account in a bank or other
         depository in that country.

5.9      If a court of competent jurisdiction and last resort holds invalid any
         patent or any of the patent claims within Licensed Patent in a final
         decision from which no appeal has or can be taken, Digirad's obligation
         to pay royalties based on that patent or claim will cease as of the
         date of that final decision. Digirad, however, shall pay any royalties
         that accrued before that decision or that are based on another patent
         or claim not involved in that decision.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    5 of 17
<Page>

                                                                       L-99-1261

5.10     Digirad has no duty to pay Berkeley Lab royalties under this Agreement
         on a Licensed Product Digirad sells to the United States Government
         including any United States Government agency. Digirad shall reduce the
         amount charged for a Licensed Product sold to the United States
         Government by an amount equal to the royalty otherwise due Berkeley
         Lab. Such royalty otherwise due Berkeley Lab will count towards the
         minimum annual royalty payments per Section 5.4.

                           6. PERFORMANCE REQUIREMENTS

6.1      Digirad shall proceed with the development, manufacture and sale of
         Licensed Products and shall use diligent commercial efforts to endeavor
         to market them within a reasonable time after the Effective Date in
         quantities sufficient to meet the market demand.

6.2      Digirad shall use diligent commercial efforts to obtain all necessary
         governmental approvals for the manufacture, use and sale of Licensed
         Products.

6.3      Digirad is entitled to exercise prudent and reasonable business
         judgment in meeting its performance requirements under this Agreement.

6.4      If Digirad is unable to perform any of the following, then Berkeley Lab
         may either terminate this Agreement or reduce this limited exclusive
         license to a nonexclusive license:

              6.4.1                  ***
                                     *** or

              6.4.2                  ***
                                     ***
                        ***

         It is the understanding of the parties hereto that any termination of
         the Agreement or reduction of this license to a nonexclusive license as
         a result of Digirad's failure to meet the specifications of Section
         6.4, shall be subject to the *** cure period set forth in Section 10.1
         below.

6.5      If Berkeley Lab grants a non-exclusive license to any other party upon
         royalty rates more favorable than those of this Agreement after
         reducing this license to a non-exclusive license, then ***
                                                     ***
                                                     ***
                           ***

6.6      Digirad and Berkeley Lab by mutual written consent may amend or extend
         the requirements of Sections 6.4.1-6.4.2 at the written request of
         Digirad in response to legitimate business reasons.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    6 of 17
<Page>

                                                                       L-99-1261

                         7. PROGRESS AND ROYALTY REPORTS

7.1      Beginning June 1, 1999 and *** thereafter, Digirad shall submit to
         Berkeley Lab a progress report covering Digirad's activities related to
         the development and testing of all Licensed Products and the obtaining
         of the governmental approvals necessary for marketing. Digirad shall
         make these progress reports for each Licensed Product until the first
         commercial sale of that Licensed Product occurs anywhere in the world.

7.2      The progress reports Digirad submits under Section 7.1 must include,
         but not be limited to, the following topics:

         7.2.1    summary of work completed related to the requirements of
                  Section 6.4;

         7.2.2    key scientific discoveries;

         7.2.3    summary of work in progress;

         7.2.4    current schedule of anticipated milestones;

         7.2.5    market plans for introduction of Licensed Products; and

         7.2.6    number of full-time equivalent (FTEs) employees or agents
                  working on the development of Licensed Products.

7.3      Digirad shall also report to Berkeley Lab in its immediately subsequent
         royalty report on the date of first commercial sale of each Licensed
         Product in the U.S. and in each other country.

7.4      After the first commercial sale of a Licensed Product anywhere in the
         world, Digirad shall make *** royalty reports to Berkeley Lab on or ***
         *** Each royalty report must cover the most recently completed *** and
         must show:

         7.4.1    the Selling Price of each type of Licensed Product sold by
                  Digirad;

         7.4.2    the number of each type of Licensed Product sold;

         7.4.3    the royalties, in U.S. dollars, payable under this Agreement
                  on those sales;

         7.4.4    the exchange rates used in calculating the royalty due;

         7.4.5    the royalties on government sales that otherwise would have
                  been due under Section 5.10; and

         7.4.6    for each sublicense, if any:

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    7 of 17
<Page>

                                                                       L-99-1261

                  7.4.6.1    the sublicensee;

                  7.4.6.2  the number, description, and aggregate Selling Prices
                           of Licensed Products that the sublicensee sold or
                           otherwise disposed of;

                  7.4.6.3  the exchange rates used in calculating the royalties
                           due Berkeley Lab from the sublicensee's sales.

7.5      If no sales of Licensed Products have been made during any reporting
         period, Digirad shall make a statement to this effect.

                              8. BOOKS AND RECORDS

8.1      Digirad shall keep books and records accurately showing all Licensed
         Products manufactured, used, or sold under the terms of this Agreement.
         Digirad shall preserve those books and records for at least *** from
         the date of the royalty payment to which they pertain and shall open
         them to inspection by representatives or agents of Berkeley Lab ***
                                                     ***
           ***

8.2      Berkeley Lab shall bear the fees and expenses of Berkeley Lab's
         representatives performing the examination of the books and records.
         But if the representatives discover an error resulting in a deficiency
         in royalties of more than *** of the total royalties due for any year,
         then Digirad shall bear the fees and expenses of these representatives
         and the difference between the earned royalties and the reported
         royalties (which shall be subject to the provisions of Article 20 (LATE
         PAYMENTS)).

                            9. LIFE OF THE AGREEMENT

9.1      Unless otherwise terminated by operation of law or by acts of the
         parties in accordance with the terms of this Agreement, this Agreement
         is in force from the Effective Date and expires concurrently with the
         last-to-expire Licensed Patent.

9.2      Any termination of this Agreement shall not affect the rights and
         obligations set forth in the following Articles:

                  Article 8         Books and Records

                  Article 12        Disposition of Licensed Products on Hand
                                    upon Termination

                  Article 13        Use of Names and Trademarks and
                                    Nondisclosure of Agreement

                  Article 14        Limited Warranty

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    8 of 17
<Page>

                                                                       L-99-1261

                  Article 19        Indemnification

                  Article 25        Export Control Laws

9.3      Termination does not affect in any manner any rights of Berkeley Lab or
         Digirad arising under this Agreement before the termination.

                         10. TERMINATION BY BERKELEY LAB

10.1     If Digirad violates or fails to perform any material term of this
         Agreement, then Berkeley Lab may give written notice of such default
         ("Default Notice") to Digirad. If Digirad fails to cure that default
         and provide Berkeley Lab with reasonable evidence of the cure within
         *** of the Default Notice, Berkeley Lab may terminate this Agreement
         and the licenses granted by a second written notice ("Termination
         Notice") to Digirad. If Berkeley Lab sends a Termination Notice to
         Digirad, this Agreement automatically terminates on the effective date
         of the Termination Notice.

                           11. TERMINATION BY DIGIRAD

11.1     Digirad at any time may terminate this Agreement in whole or as to any
         portion of Licensed Patents by giving written notice to Berkeley Lab.
         Digirad's termination of this Agreement will be effective *** after its
         notice. If that termination is without cause within *** years of the
         Effective Date, Digirad shall ***
                                            ***
                  ***

          12. DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION

12.1     Within *** of termination of this Agreement for any reason, Digirad
         shall provide Berkeley Lab with a written inventory of all Licensed
         Products in process of manufacture or in stock. Digirad shall make
         diligent efforts to dispose of those Licensed Products within *** of
         termination. The sale of any Licensed Product within *** is subject to
         the terms of this Agreement. Digirad shall cease sales of ***
         *** after termination.

         13. USE OF NAMES AND TRADEMARKS AND NONDISCLOSURE OF AGREEMENT

13.1     In accordance with California Education Code Section 92000, Digirad
         shall not use in advertising, publicity or other promotional activities
         any name, trade name, trademark, or other designation of the University
         of California, nor shall Digirad so use "Berkeley Lab" (including any
         contraction, abbreviation, or simulation of any of the foregoing)
         without

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    9 of 17
<Page>

                                                                       L-99-1261

         Berkeley Lab's prior written consent. As the sole exception to the
         above prohibition, Digirad shall give appropriate credit to the
         inventor(s) and Berkeley Lab at scientific symposia, and in technical
         publications in scientific journals where the licensed technology is
         referenced. Berkeley Lab shall not use in advertising, publicity or
         other promotional activities any name, trade name, or other designation
         of Digirad without its prior written consent except as set forth in
         Section 13.2 below.

13.2     Neither party may disclose the terms or existence of this Agreement to
         a third patty without express written permission of the other party,
         except when required under either the California Public Records Act or
         other applicable law or court order or by Berkeley Lab's contracts with
         the DOE or any other Federal or State entity. Notwithstanding the
         foregoing, Berkeley Lab may disclose the existence of this Agreement
         and the extent of the grant in Article 3, but shall not otherwise
         disclose the terms of this Agreement, except to the DOE.

13.3     The Proprietary Information Exchange Agreement between Digirad and the
         Regents of the University of California as Managers of the Lawrence
         Berkeley National Laboratory, as attached hereto as Exhibit A, shall
         remain in effect through the term outlined in the Proprietary
         Information Exchange Agreement.

                              14. LIMITED WARRANTY

14.1     Berkeley Lab warrants to Digirad that it has the lawful right to grant
         this license.

14.2     Except as set forth above, this license and the associated Invention(s)
         are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
         PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. BERKELEY
         LAB MAKES NO REPRESENTATION OR WARRANTY THAT LICENSED PRODUCTS WILL NOT
         INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT.

14.3     IN NO EVENT WILL BERKELEY LAB OR DIGIRAD BE LIABLE FOR ANY INCIDENTAL,
         SPECIAL OR CONSEQUENTIAL DAMAGES INCURRED BY THE OTHER PARTY HERETO
         RESULTING FROM EXERCISE OF THIS LICENSE OR THE USE OF THE INVENTION(S)
         OR LICENSED PRODUCTS UNDER THIS AGREEMENT. THIS PROVISION, 14.3, DOES
         NOT APPLY TO INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES AWARDED IN A
         JUDGEMENT FOR A THIRD PARTY AGAINST A PARTY OR THE PARTIES HERETO.

14.4     Except as set forth above, nothing in this Agreement may be construed
         as:

         14.4.1   a warranty or representation by Berkeley Lab as to the
                  validity or scope of any of Berkeley Lab's rights in Licensed
                  Patents;

                                    10 of 17
<Page>

                                                                       L-99-1261

         14.4.2   a warranty or representation that anything made, used, sold or
                  otherwise disposed of under any license granted in this
                  Agreement is or will be free from infringement of patents of
                  third parties;

         14.4.3   an obligation to bring or prosecute actions or suits against
                  third parties for patent infringement, except as specifically
                  provided for in Article 16 (Patent Infringement);

         14.4.4   a grant by implication, estoppel or otherwise of any license
                  or rights under any patents of Berkeley Lab other than
                  Licensed Patents, regardless of whether such patents are
                  dominant or subordinate to Licensed Patents; or

         14.4.5   an obligation to furnish any know-how not provided in Licensed
                  Patents.

                     15. PATENT PROSECUTION AND MAINTENANCE

15.1     Berkeley Lab shall diligently maintain the United States patents for
         Licensed Patents (including any future patent rights provided for in
         Section 2.4) using counsel of its choice that is reasonably acceptable
         to Digirad. Berkeley Lab shall bear the cost of pre-paring, filing,
         prosecuting and maintaining any United States patent covered by this
         Agreement.

15.2     Berkeley Lab has filed foreign patent applications corresponding to the
         PCT Application referred to in Section 2.4 (namely US 97/20173) as
         follows:

(a)    European Patent Office (EPO), designating

(i)    ***

(ii)   ***

(iii)  ***

(iv)   ***

(v)    ***

(vi)   ***

(vii)  ***

(viii) ***

(ix)   ***

(x)    ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    11 of 17
<Page>

                                                                       L-99-1261

(xi)   ***

(xii)  ***

(b)    ***

Berkeley Lab has no obligation to take action to file or prosecute foreign
patent applications on behalf of Digirad until the following occurs:

         15.2.1   (With the exception of the three countries listed in 15.3
                  below) Digirad makes that request in writing to Berkeley Lab
                  within *** after the Effective Date. The absence of the
                  required notice from Digirad to Berkeley Lab acts as an
                  election not to proceed on protecting foreign rights.

         15.2.2   That notice also identifies the countries Digirad desires.

         15.2.3   Digirad pays Berkeley Lab the foreign license fee as set forth
                  in paragraph 15.4

15.3     Digirad agrees to pay Berkeley Lab *** , upon the day of execution of
         this Agreement, for the foreign patent counterparts to the U.S.
         application for the following countries: ***

15.4     The foreign license fee for each foreign counterpart in addition to
         those listed in Section 15.3 to a United States patent application
         shall be *** for each national filing or for each country designated in
         the PCT filing for entry into the national phase, European Patent
         Convention ("EPC") filing, or similar regional filing.

15.5     Berkeley Lab shall bear the expense of preparing, filing, prosecuting
         and securing all foreign patent applications that Berkeley Lab files at
         Digirad's request (pursuant to 15.2 above). Digirad shall bear the
         expense of ***
                                                     ***
                                                     ***

15.6     Berkeley Lab shall promptly provide Digirad with copies of all relevant
         documentation so that Digirad is informed of the continuing prosecution
         of Licensed Patents and any foreign patent applications Berkeley Lab
         files under Section 15.2. Additionally, Berkeley Lab shall provide
         Digirad a *** *** summarizing the status of the Licensed Patents and
         any foreign patent applications Berkeley Lab files under Section 15.2.
         Digirad shall keep this documentation confidential. Berkeley Lab shall
         use all reasonable efforts to amend any patent application to include
         claims reasonably requested by Digirad to protect the products
         contemplated to be sold under this Agreement.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    12 of 17
<Page>

                                                                       L-99-1261

                             16. PATENT INFRINGEMENT

16.1     If either party learns of the substantial infringement of any of
         Licensed Patents, the party shall so inform the other party in writing
         and shall provide the other party with reasonable evidence of the
         infringement. During the period and in a jurisdiction where Digirad has
         exclusive rights under this Agreement, ***
                                                     ***
                                                     ***        Both parties
         shall use their best efforts in cooperation with each other to
         terminate such infringement without litigation.

16.2                                                          ***
                                                              ***
                                                              ***

16.3                                                          ***
                                                              ***
                                                              ***

16.4                                                          ***
                                                              ***
                                                              ***

                                   17. WAIVER

17.1     The waiver of any breach of any term of this Agreement does not waive
         any other breach of that or any other term.

                                 18. ASSIGNMENT

18.1     This Agreement is binding upon and shall inure to the benefit of
         Berkeley Lab, its successors and assigns. Upon written notice to
         Berkeley Lab, Digirad may assign this Agreement to a Digirad wholly
         owned subsidiary or to a purchaser or acquirer of all or substantially
         all of the business or assets of Digirad. Any other attempt by Digirad
         to assign this Agreement is void unless Digirad obtains the prior
         written consent of Berkeley Lab. Berkeley Lab shall not unreasonably
         withhold or delay that consent.

                               19. INDEMNIFICATION

19.1     Digirad shall indemnify, hold harmless and defend Berkeley Lab and the
         U.S. Government and their officers, employees, and agents; the sponsors
         of the research that led to the Invention; and the inventors of the
         patents and patent applications in Licensed Patents against any and all
         claims, suits, losses, damage, costs, fees, and expenses resulting from
         or arising out of exercise of this license or any sublicense. Berkeley
         Lab shall promptly notify Digirad in writing of any claim or suit
         brought against Berkeley Lab in respect of which Berkeley Lab intends
         to invoke the provisions of this Article 19

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    13 of 17
<Page>

                                                                       L-99-1261

         (INDEMNIFICATION).                          ***
                                                     ***
                                                     ***

19.2     Digirad, at its sole expense, shall insure its activities in connection
         with the work under this Agreement and obtain and keep in force
         Comprehensive or Commercial Form General Liability Insurance
         (contractual liability and products liability included) or equivalent
         program of self-insurance with limits as follows:

         19.2.1   Each Occurrence                                     $   ***
         19.2.2   Products/Completed Operations Aggregate             $   ***
         19.2.3   Personal and Advertising Injury                     $   ***
         19.2.4   General Aggregate (commercial form only)            $   ***

19.3     The coverages and limits referred to in this Article 19 do not in any
         way limit the liability of Digirad. Digirad shall furnish Berkeley Lab
         with certificates of insurance, including renewals, evidencing
         compliance with all requirements at least *** prior to the first
         commercial sale, use, practice or distribution of a Licensed Product.

         19.3.1   If such insurance is written on a claims-made form, coverage
                  shall provide for a retroactive date of placement on or before
                  the Effective Date.

         19.3.2   Digirad shall maintain the general liability insurance
                  specified during: (a) the period that the Licensed Product is
                  being commercially distributed or sold (other than for the
                  purpose of obtaining regulatory approvals) by Digirad or by a
                  sublicensee or agent of Digirad, and (b) a reasonable period
                  thereafter, but in no event less than five years.

19.4     The insurance coverage of Section 19.2 must:

         19.4.1   Provide for *** advance written notice to Berkeley Lab of any
                  modification of any such coverage and provide immediate notice
                  of cancellation of such coverage.

         19.4.2   Indicate that DOE and "The Regents of the University of
                  California" are endorsed as additional insureds, but only with
                  respect to the subject matter of this Agreement.

         19.4.3   Include a provision that the coverages are primary and do not
                  participate with, nor are excess over, any valid and
                  collectible insurance or program of self-insurance carried or
                  maintained by Berkeley Lab.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    14 of 17
<Page>

                                                                       L-99-1261

                                20. LATE PAYMENTS

20.1     Excepting issues arising from Section 26.1, if Digirad does not make a
         payment to Berkeley Lab when due, Digirad shall pay to Berkeley Lab ***
                                                     ***
                                                     ***
                  ***

                                   21. NOTICES

21.1     Any payment, notice or other communication this Agreement requires or
         permits either party to give must be in writing to the appropriate
         address given below, or to such other address as one party designates
         by written notice to the other party. The parties deem payment, notice
         or other communication to have been properly given and to be effective
         (a) on the date of delivery if delivered in person; (b) on the fourth
         day after mailing if mailed by first-class mail, postage paid; (c) on
         the second day after delivery to an overnight courier service such as
         Federal Express, if sent by such a service; or (d) upon confirmed
         transmission by telecopier. The parties addresses are as follows:

         For payments to Berkeley Lab:       For all other notices to
                                             Berkeley Lab:

         Ernest Orlando Lawrence             Ernest Orlando Lawrence
         Berkeley National Laboratory        Berkeley National Laboratory
         Accounting/Financial Management     Technology Transfer Department
         P.O. Box 528                        Mailstop 90-1070
         Berkeley, California 94701          One Cyclotron Road
         Attention: Licensing Accountant     Berkeley, California 94720
         Fax: 510/486-5995                   Attention: Licensing Manager
         Telephone: 510/486-7113             Fax: 510/486-6457
                                             Telephone: 510/486-6467

         In the case of Digirad:

         Digirad Corporation
         9350 Trade Place
         San Diego, California 92126-6334
         Attention:  President
         Fax:  619-549-7714
         Telephone:  619-578-5300

                              22. U.S. MANUFACTURE

22.1     Digirad shall have Licensed Products produced for sale in the United
         States manufactured substantially in the United States so long as
         Digirad has current exclusive rights in the Field of Use.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                    15 of 17
<Page>

                                                                       L-99-1261

                               23. PATENT MARKING

23.1     Digirad shall mark all Licensed Products made, used or sold under this
         Agreement, or their containers, in accordance with the applicable
         patent marking laws.

                     24. GOVERNMENT APPROVAL OR REGISTRATION

24.1     If the law of any nation requires that any governmental agency either
         approve or register this Agreement or any associated transaction,
         Digirad shall assume all legal obligations to do so. Digirad shall
         notify Berkeley Lab if it becomes aware that this Agreement is subject
         to a U.S. or foreign government reporting or approval requirement.
         Digirad shall make all necessary filings and pay all costs, including
         fees, penalties, and all other costs associated with such reporting or
         approval process. Berkeley Lab shall fully cooperate with Digirad, to
         the extent it is able to do so within the law and established Berkeley
         Lab policy, to provide documentation and testimony to obtain such
         approval or registration, at Digirad's sole expense.

                             25. EXPORT CONTROL LAWS

25.1     Digirad shall observe all applicable United States and foreign laws and
         regulations with respect to the transfer of Licensed Products and
         related technical data, including, with-out limitation, the
         International Traffic in Arms Regulations (ITAR) and the Export
         Administration Regulations.

                                26. FORCE MAJEURE

26.1     If a party's performance required under this Agreement is rendered
         impossible or unfeasible due to any catastrophes or other major events
         beyond its reasonable control, including, without limitation, the
         following, the parties are excused from performance, war, riot, and
         insurrection; laws, proclamations, edicts, ordinances or regulations;
         strikes, lockouts or other serious labor disputes; and floods, fires,
         explosions, or other natural disasters. When such events abate, the
         parties' respective obligations under this Agreement must resume.

                                27. MISCELLANEOUS

27.1     The headings of the several sections are inserted for convenience of
         reference only and are not intended to be a part of or to affect the
         meaning or interpretation of this Agreement.

27.2     This Agreement is not binding upon the parties until it is signed below
         on behalf of each party.

27.3     No amendment or modification hereof shall be valid or binding upon the
         parties unless made in writing and signed on behalf of each party.

                                    16 of 17
<Page>

                                                                       L-99-1261

27.4     This Agreement embodies the entire and final understanding of the
         parties on this subject. It supersedes any previous representations,
         agreements, or understandings, whether oral or written.

27.5     If a court of competent jurisdiction holds any provision of this
         Agreement invalid, illegal or unenforceable in any respect, this
         Agreement must be construed as if that invalid or illegal or
         unenforceable provision is severed from the Agreement, provided,
         however, that the parties shall negotiate in good faith substitute
         enforceable provisions that most nearly effect the parties' intent in
         entering into this Agreement.

27.6     This Agreement must be interpreted under California law without regard
         to principles of conflicts of laws.

Berkeley Lab and Digirad execute this Agreement in duplicate originals through
their duly authorized respective officers in one or more counterparts, that
taken together, are but one instrument.

THE REGENTS OF THE UNIVERSITY               DIGIRAD CORPORATION
OF CALIFORNIA, THROUGH THE
ERNEST ORLANDO LAWRENCE
BERKELEY NATIONAL LABORATORY

By    /S/ PIERMARIA T. ODDONE             By       /S/ SCOTT HUENNEKENS
   -----------------------------             ---------------------------------
                  (signature)                          (signature)

By      PIERMARIA T.  ODDONE              By         SCOTT HUENNEKENS
   ------------------------------            ---------------------------------
            (Please Print)                            (Please Print)

Title    DEPUTY DIRECTOR                  Title    PERS. & COO
      ---------------------------                -----------------------------

Date     MAY 16, 1999                     Date     5-19, 1999
     ----------------------------              -------------------------------

Approved as to form

         /S/ GLENN R. WOODS
----------------------------------------
GLENN R. WOODS
LAWRENCE BERKELEY NATIONAL LABORATORY

                                    17 of 17
<Page>

                         Exhibit A to License Agreement

                   PROPRIETARY INFORMATION EXCHANGE AGREEMENT

         This AGREEMENT made and entered into as of this 23rd day of April 1,
1999 by and between DIGIRAD, a Delaware corporation, whose address is 9350 Trade
Place, San Diego, California 92126-6334 and The Regents of the University of
California as Managers of the Lawrence Berkeley National Laboratory, whose
address is 1 Cyclotron Road, Berkeley, CA 94720.

         WHEREAS, the parties hereto are undertaking negotiations towards the
development of a license agreement between them, and

         WHEREAS, in furtherance of such license, each undersigned party (the
"Receiving Party") understands that the other party (the "Disclosing Party") has
disclosed or may disclose information relating to the Disclosing Party's
business and/or intellectual property (including, without limitation, chemical
formulas, computer programs, software, technical drawings, names and expertise
of employees and consultants, know-how, formulas processes, ideas, inventions
(whether patentable or not), schematics and other technical business, financial,
customer and product development plans, forecasts, strategies and information,
and any and all information, technical or otherwise related to describing
Digirad's ***
                                            ***
                                            ***
sub-assemblies and related assemblies for use in medical imaging systems and
other applications), information which to the extent previously, presently, or
subsequently disclosed to the Receiving Party is hereinafter referred to as
"Proprietary Information" of the Disclosing Party.

         NOW, THEREFORE, in consideration of the parties' discussions and any
access the Receiving Party may have to Proprietary Information of the Disclosing
Party, the parties agree that any information received by one party from the
other shall be governed by the following terms and conditions:

Definition:

         "Proprietary Information" shall not include information which:

         (a)      was rightfully in possession of or known to the Receiving
Party prior to receiving it from the Disclosing Party; or

         (b)      is or becomes part of the public knowledge or literature by
acts other than those of the Receiving Party and without fault of the receiving
Party; or

         (c)      was rightfully disclosed to the Receiving Party by a third
party provided the Receiving Party complies with restrictions imposed by the
third party; or

         (d)      is transmitted after the expiration of this Agreement; or

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                     1 of 4
<Page>

         (e)      is disclosed by the Receiving Party under a valid order
created by a court or government agency, provided that the Receiving Party
provides prior written notice to the Disclosing Party of such obligation and the
opportunity to oppose such disclosure.

         (f)      the Receiving Party develops independently, subsequent to
receipt of Proprietary Information and for which Receiving Party can demonstrate
by written records that independent development occurred without knowledge or
use of Proprietary Information.

HANDLING OF PROPRIETARY INFORMATION:

         The Receiving Party agrees to (i) hold the Disclosing Party's
Proprietary Information in strict confidence as a fiduciary and to take
reasonable precautions to protect such Proprietary Information and (ii) handle
the Proprietary Information in the same manner that it handles its own
proprietary information of like importance, but with at least reasonable degree
of care, for a period of five (5) years after the date of disclosure.

LIMITATION ON DISCLOSURE:

         The Receiving Party shall not disclose, in whole or in part, such
Proprietary Information to any third party without the prior written consent of
the Disclosing Party for the period that such information is to be handled as
proprietary. The Receiving Party may disclose Proprietary Information only to
those of its employees who would require knowledge of such Proprietary
Information for the purposes contemplated by this Agreement and who is similarly
bound in writing.

LIMITATION OF USE:

         The Receiving Party shall make no use, in whole or in part, of any such
Proprietary Information other than in furtherance of the purpose of this
Agreement without the prior written consent of the Disclosing Party.

         If the purpose of the information exchange is the preparation of a
proposal to the United States Government, Proprietary Information of either
party may be incorporated into the proposal to the United States Government,
provided that the proposal document bears the restrictive legend contained in
Federal Acquisition Regulation 52.215-12 or a substantially similar successor
provision.

TERM:

         This Agreement shall expire one (1) year from the date recited in the
first paragraph of this Agreement. With the exception of information disclosed
in accordance with the provisions of the License Agreement for Detector between
Digirad Corporation and the Regents of the University of California through the
Ernest Orlando Lawrence Berkeley Laboratory, immediately upon a request by the
Disclosing Party at any time (which will be effective if actually received or
three days after mailed first class postage prepaid to the Receiving Party's
address herein), the Receiving Party will turn over to the Disclosing Party all
Proprietary Information of the Disclosing Party and all documents or media
containing any such Proprietary Information and any and all copies or extracts
thereof. The Receiving Party understands that

                                     2 of 4
<Page>

nothing herein (i) requires the disclosure of any Proprietary Information of the
Disclosing Party, which shall be disclosed if at all solely at the option of the
Disclosing Party (in particular, but without limitation, any disclosure is
subject to compliance with expert control laws and regulations), or (ii)
requires the Disclosing Party to proceed with any proposed transaction or
relationship in connection with which Proprietary Information may be disclosed.
The party's obligations with respect to Proprietary Information disclosed to it
prior to expiration/termination shall survive expiration/termination.

RELATIONSHIP OF PARTIES:

         This Agreement is intended to provide only for the handling and
protection of Proprietary Information exchanged or disclosed hereunder, and
shall not be construed as a Teaming, Joint Venture, Partnership, or other
similar arrangement. Specifically, this Agreement shall not be construed in any
manner to be an obligation to enter into a contract, nor shall it result in any
claim whatsoever for reimbursement of costs.

NO LICENSE:

         Neither the execution of this agreement nor the furnishing of any
Proprietary Information hereunder shall be construed as granting either
expressly, by implication, estoppel or otherwise, any license other than as
expressly set forth herein under any invention, patent, copyright, trade secret,
mask work right, or any other intellectual property right, now or hereafter
owned or controlled by the party furnishing same.

U.S.  GOVERNMENT REGULATIONS:

         A party receiving Proprietary Information shall comply with all
relevant United States Government regulations, including the International
Traffic in Arms Regulations and the Export Administration Act.

MISCELLANEOUS:

         Each party shall perform its respective obligations hereunder without
charge to the other.

         Except to the extent permitted by the License Agreement for Detector
between Digirad Corporation and the Regents of the University of California
through the Ernest Orlando Lawrence Berkeley Laboratory, neither party will
refer to this Agreement or use the other party's name in any form of publicity
or advertising directly or indirectly, without the prior written consent of the
party whose name is proposed for use.

         Except as to a sale of the business to which this Agreement relates or
transfer of the management of the Ernest Orlando Lawrence Berkley Laboratory,
the rights and obligations of each party under this Agreement may not be
assigned or transferred to any person, firm or corporation, without the express
prior written consent of the other party, which consent will not be unreasonably
withheld.

         Neither party makes any representations regarding the accuracy,
completeness, or freedom from defects of the information disclosed, or with
respect to infringement of the rights of others.

                                     3 of 4
<Page>

         The Receiving Party acknowledges and agrees that due to the unique
nature of the Disclosing Party's Proprietary Information, there may be no
adequate remedy at law for any breach of its obligations hereunder, that any
such breach may allow the Receiving Party or third parties to unfairly compete
with the Disclosing Party resulting in irreparable harm to the Disclosing Party,
and therefore, that upon any such breach or any threat thereof, the Disclosing
Party may be entitled to appropriate equitable relief in addition to whatever
remedies it might have at law. The Receiving Party will notify the Disclosing
Party in writing immediately upon the occurrence of any such unauthorized
release or other breach of which it is aware. In the event that any of the
provisions of this Agreement shall be held by a court or other tribunal of
competent jurisdiction to be illegal, invalid or unenforceable, such provisions
shall be limited or eliminated to the minimum extent necessary so that this
Agreement shall otherwise remain in full force and effect.

ENTIRE AGREEMENT:

         This Agreement represents the entire agreement of the parties
pertaining to the subject matter of the Agreement, and supersedes any and all
prior oral discussions and/or written correspondence or agreements between the
parties with respect thereto.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed in duplicate original copies by their respective duly authorized
representatives.

DIGIRAD                                  The Regents of the University of
                                         California Acting as Manager of the
                                         Lawrence Berkeley Laboratory

By:                                      By:
    ------------------------------           -----------------------------

Name:                                    Name:
      ----------------------------             ---------------------------

Title:                                   Title:
       ---------------------------              --------------------------

Date:                                    Date:
      ----------------------------             ---------------------------

                                     4 of 4
<Page>

                                  AMENDMENT #1
                                       TO
                         LICENSE AGREEMENT FOR DETECTOR

This Amendment (the "Amendment"), effective as of the signing date of the last
party to sign below, is entered into by The Regents of the University of
California ("The Regents"), Department of Energy contract-operators of the
Ernest Orlando Lawrence Berkeley National Laboratory ("LBNL"), 1 Cyclotron Road,
Berkeley, CA 94720, (jointly, "Berkeley Lab"), and Digirad Corporation
("Digirad"), a Delaware corporation having its principal place of business at
9350 Trade Place, San Diego, CA 92126-6330.

         THE PARTIES ENTERED INTO A LICENSE AGREEMENT FOR DETECTOR, REFERENCE
         NUMBER L-90-1261 (THE "AGREEMENT"), EFFECTIVE DATE OF MAY 19, 1999. THE
         PARTIES NOW DESIRE TO AMEND THE AGREEMENT BY EXPANDING THE LICENSE TO
         INCLUDE A NON-EXCLUSIVE FIELD OF USE (AS DEFINED BELOW) PURSUANT TO THE
         TERMS AND CONDITIONS HEREIN. CAPITALIZED TERMS HEREIN SHALL HAVE THE
         MEANING AS SET FORTH IN THE AGREEMENT EXCEPT AS OTHERWISE DEFINED IN
         THIS AMENDMENT.

The parties agree as follows:

1.       Section 2.2 of the Agreement is hereby deleted in its entirety and
         replaced with the following:

         2.2      "Field of Use" and "Non-Exclusive Field of Use":

                  2.2.1    "Field of Use" means the development, production and
                           use of ***
                                                              ***
                                                              ***

                  2.2.2    "Non-Exclusive Field of Use" means the development,
                           production and use of ***
                                                              ***
                                                              ***

2.       Section 2.4 of the Agreement is hereby deleted in its entirety and
         replaced with the following:

         2.4      "Licensed Patents" means patent rights to any subject matter
                  claimed in or covered by any of the following:

                  2.4.1    US Patent Number ***
                                                              ***
                                                              ***

                  2.4.2    Any resulting patent issued in Germany or France
                           arising from European Patent Convention Application
                           ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                                                            pg 1
<Page>

                                                              ***
                                                              ***

                  2.4.3    Japan Patent Application  ***
                                                              ***
                                                              ***

                  2.4.4    with respect to Sections 2.4.1 to 2.4.3, any
                           division, reexamination, continuation,
                           continuation-in-part (excluding new matter contained
                           and claimed in that continuation-in-part), or of
                           which such application is a successor; any patents
                           issuing on any of the foregoing, and all renewals,
                           reissues and extensions thereof, or other equivalents
                           of a renewal, reissues, and extensions thereof.

3.       Section 3.1 of the Agreement is hereby deleted in its entirety and
         replaced with the following:

         3.1      Subject to the limitations set forth in this Agreement,
                  Berkeley Lab grants to Digirad:

                  3.1.1    a nontransferable (subject to Section 18.1), limited
                           (by the terms of Sections 3.2 and 3.7) worldwide
                           exclusive, royalty-bearing license, under Licensed
                           Patents, only in the Field of Use, to develop, make,
                           have made, use, practice, sell, have sold, and lease
                           the Licensed Products.

                  3.1.2    a nontransferable (subject to Section 18.1),
                           nonexclusive worldwide, royalty-bearing license,
                           under Licensed Patents, only within the Non-Exclusive
                           Field of Use, to develop, make, have made, use,
                           practice, sell, and lease the Licensed Products.

4.       Section 4.1 of the Agreement is hereby deleted in its entirety and
         replaced with the following:

         4.1      As consideration for the licenses granted hereunder:

                  4.1.1    within the Field of Use, Digirad shall pay Berkeley
                           Lab a license issue fee of ***
                                                              ***
                                                              ***

                  4.1.2    within the Non-Exclusive Field of Use, Digirad shall
                           pay Berkeley Lab a license issue fee of ***
                                                              ***
                                                              ***
                                    ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                                                            pg 2
<Page>

5.       Section 5.1 of the Agreement is hereby deleted in its entirety and
         replaced with the following:

         5.1      Digirad shall pay to Berkeley Lab an earned royalty of:

                  5.1.1    *** of the Selling Price of each Licensed Product
                           Digirad sells within the Field of Use;

                  5.1.2    *** of the Selling Price of each Licensed
                           Product Digirad sells within the Non-Exclusive
                           Field of Use;

6.       Section 5.4 of the Agreement is hereby deleted in its entirety and
         replaced with the following:

         5.4      Digirad shall pay to Berkeley Lab by *** of each year the
                  difference between the earned royalties for that calendar year
                  Digirad has already paid to Berkeley Lab for the Field of Use
                  and Non-Exclusive Field of Use and the minimum annual royalty
                  set forth in the following schedules for the Field of Use and
                  Non-Exclusive Field of Use. Berkeley Lab shall credit that
                  minimum annual royalty paid against the earned royalty due and
                  owing for the calendar year in which Digirad made the minimum
                  payment; provided that the earned royalties and minimum annual
                  royalties for the Field of Use shall be treated separately
                  from and independent of the earned royalties and minimum
                  annual royalties for the Non-Exclusive Field of Use.

<Table>
<Caption>
      ------------------------------------ ----------------------------------- -------------------------------
                 CALENDAR YEAR             MINIMUM ANNUAL ROVALTY FOR FIELD     MINIMUM ANNUAL ROYALTY FOR
                                                         OF USE                  NON-EXCLUSIVE FIELD OF USE
      ------------------------------------ ----------------------------------- -------------------------------
      <S>                                  <C>                                  <C>
                     1999                                 ***                               N/A
      ------------------------------------ ----------------------------------- -------------------------------
                     2000                                 ***                               N/A
      ------------------------------------ ----------------------------------- -------------------------------
                     2001                                 ***                               ***
      ------------------------------------ ----------------------------------- -------------------------------
                     2002                                 ***                               ***
      ------------------------------------ ----------------------------------- -------------------------------
                     2003                                 ***                               ***
      ------------------------------------ ----------------------------------- -------------------------------
                     2004                                 ***                               ***
      ------------------------------------ ----------------------------------- -------------------------------
      2005 and each year thereafter                       ***                               ***
      ------------------------------------ ----------------------------------- -------------------------------
</Table>

7.       Sections 6.4 and 6.5 of the Agreement are hereby deleted in their
         entirety and replaced with the following:

         6.4      If Digirad is unable to perform any of the following, then
                  Berkeley Lab may either terminate this Agreement or reduce the
                  limited exclusive license within the Field of Use to a
                  non-exclusive license within the Field of Use:

                  6.4.1    With regard to the Field of Use:

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                                                            pg 3
<Page>

                           6.4.1.1          ***
                                            ***

                           6.4.1.2          ***
                                            ***

                  6.4.2    With regard to the Non-Exclusive Field of Use:

                           6.4.2.1                   ***

                           6.4.2.2                   ***

                           6.4.2.3                   ***

                           6.4.2.4                   ***

                           6.4.2.5                   ***

                           6.4.2.6                   ***
                                                     ***

                  It is the understanding of the parties hereto that any
                  termination of the Agreement or reduction of this license to a
                  non-exclusive license as a result of Digirad's failure to meet
                  the specifications of Section 6.4 shall be subject to the ***
                  day cure period set forth in Section 10.1 below.

         6.5      If Berkeley Lab grants a non-exclusive license to any other
                  party within the Field of Use upon royalty rates more
                  favorable than those of this Agreement after reducing the this
                  license within the Field of Use to a non-exclusive license
                  within the Field of Use, then ***
                                                                       ***
                                                                       ***
                                            ***

8.       The reporting obligations of Section 7 shall apply to both the Field of
         Use and Non-Exclusive Field of Use, separately and independently.
         Beginning *** thereafter, Digirad shall submit to Berkeley Lab a
         progress reports covering Digirad's activities related to the
         development and testing of all Licensed Products within the
         Non-Exclusive Field of Use and obtaining of the government approvals
         necessary for marketing as required pursuant to Section 7.1 ET. SEQ.

9.       Section 11.1 of the Agreement is hereby deleted in its entirety and
         replaced with the following:

         11.1     Digirad at any time may terminate this Agreement in whole or
                  as to any portion of Licensed Patents by giving written notice
                  to Berkeley Lab. Digirad's termination

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                                                            pg 4
<Page>

                  of this Agreement will be effective *** days after its notice.
                  If that termination pertains to the Field of Use and is
                  without cause within *** years of the Effective Date, Digirad
                  shall ***
                                            ***

10.      Section 15.2 of the Agreement is hereby deleted in its entirety.

11.      Section 15.5 of the Agreement is hereby deleted in its entirety and
         replaced with the following:

         15.5                                    ***
                                                 ***
                                                 ***

12.      Section 15.6 of the Agreement is hereby deleted in its entirety and
         replaced with the following:

         15.6     Berkeley Lab shall promptly provide Digirad with copies of all
                  relevant documentation so that Digirad is informed of the
                  continuing prosecution of Licensed Patents. Additionally, upon
                  *** Berkeley Lab shall provide Digirad with a report
                  summarizing the status of the Licensed Patents. Digirad shall
                  keep this documentation confidential. Berkeley Lab shall use
                  all reasonable efforts to amend any patent application to
                  include claims reasonably requested by Digirad to protect the
                  products contemplated to be sold under this Agreement.

13.      Digirad acknowledges and agrees that Section 16 applies, other than the
         first sentence of Section 16.1, only to jurisdictions in which Digirad
         has exclusive rights under the Agreement. Thus, except for that first
         sentence of Section 16.1, the entirety of Section 16 will not apply to
         the Licensed Products insofar as they are within the Non-Exclusive
         Field of Use.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                                                            pg 5
<Page>

14.      Except as specifically amended herein, the Agreement is hereby ratified
         and confirmed.

Berkeley Lab and Digirad execute this Agreement in duplicate originals through
their authorized respective officers in one or more counterparts that, taken
together, are but one instrument.

THE REGENTS OF THE UNIVERSITY                 DIGIRAD CORPORATION
OF CALIFORNIA, THROUGH THE
ERNEST ORLANDO LAWRENCE
BERKELEY NATIONAL LABORATORY

By   /S/ PIERMARIA ODDONE                     By    /S/ SCOTT HUENNEKENS
  -----------------------------------            ---------------------------
          (Signature)                                    (Signature)

By    PIERMARIA ODDONE                        By    SCOTT HUENNEKENS
  -----------------------------------             --------------------
Title    DEPUTY LABORATORY DIRECTOR           Title    PRESIDENT AND CEO
     --------------------------------                ---------------------
Date    5-24-01                               Date    5-11-01
    ---------------------------------               -----------

Approved as to form

/S/ GLENN R. WOODS
-------------------------------------
GLENN R. WOODS
LAWRENCE BERKELEY NATIONAL LABORATORY

                                                                            pg 6<Page>

                                                                    EXHIBIT 10.2

                           SOFTWARE LICENSE AGREEMENT

         This Software License Agreement ("Agreement") is entered into under
seal this 16th day of June, 1999 (the "Effective Date") by and between Segami
Corporation, a Maryland corporation having its principal offices at 12624 Golden
Oak Drive, Ellicott City MD 21042 ("Segami"), and Digirad Corporation
("Digirad"), a Delaware corporation having its principal offices at 9350 Trade
Place. San Diego CA 92126.

                             Statement of Intention

         A.       Segami is in the business of the development and sale of
                  software for gamma camera image acquisition, processing and
                  display. Segami's current software is called Mirage

         B.       Digirad desires to purchase software from Segami for the
                  purpose of gamma camera image acquisition, processing and
                  display which will interface with Digirad's solid state gamma
                  camera.

         C.       Digirad desires to package the Mirage software and Digirad's
                  hardware for resale as a single product, identifiable only as
                  a Digirad product.

         In consideration of the mutual promises and covenants herein contained,
the receipt and sufficiency of which are hereby acknowledged, the parties agree
under seal as follows:

         1.       DEFINITIONS. For the purposes of this Agreement, the following
terms, when used herein, have the following meaning.

"Base Software"-The existing Mirage software described in EXHIBIT D hereto in
object and executable code forms, and all updates, enhancements, revisions,
modifications, modules and or sub-modules thereto and all permitted copies,
except that Base Software does not include the Interface Development.

"Interface Development"-The new code written and modifications made to the Base
Software which will allow use of the Base Software with Digirad's current
hardware, in object and executable code forms, and all updates, enhancements,
revisions, modifications, modules and or sub-modules thereto and all permitted
copies.

"Product" - Digirad's solid state gamma camera bundled together with the Base
Software and Interface Development.

         2.       LICENSE TO DIGIRAD. Subject to all the terms of this
Agreement, Segami grants to Digirad a nonexclusive worldwide, fully paid-up
license:

         (a)      to sublicense the Base Software to end-users only in
connection with the sale and use of the Products; any such sublicense shall be
pursuant to a sublicense agreement for Segami's

                                  Page 1 of 10

<Page>

benefit that contains applicable similar restrictions and obligations imposed on
Digirad hereunder.

         (b)      to use, adopt, reproduce, display, perform, test, demonstrate
and distribute the Base Software as necessary to market, sale and distribute the
Products.

         (c)      sublicense to third parties the distribution rights for the
Products and Base Software; any such sublicense shall be pursuant to a
sublicense agreement for Segami 's benefit that contains applicable similar
restrictions and obligations imposed on Digirad hereunder.

The balance of this Section 2 notwithstanding, the license granted to Digirad
shall not include the right to sublicense, sell or distribute the Base Software
independently and separate from the Product, with the understanding that Digirad
may demonstrate the Base Software or distribute demonstration models of the Base
Software, limited in function, for use on systems independent from the Product.

         3.       USE/LICENSE FEES.

                  3.1      USE. Segami hereby grants Digirad the right to
package and bundle the Base Software with the Product, the Interface Development
and Digirad hardware for sale to end-users by Digirad or its subdistributors.

                  3.2      LICENSE FEES. Digirad shall pay a License Fee (the
"License Fee") to Segami, in accordance with the attached Exhibit A, for each
copy of the Base Software distributed to any end-user, unless otherwise agreed
upon in writing by Segami. Payment of the License Fee shall be made by Digirad
and tendered to Segami at the sooner of *** days after customer payment or ***
days after customer installation. Digirad will receive a reasonable number of
demonstration versions of the Base Software including the dongle keys ("Keys")
for using such versions ("Demo Versions") to be used for customer demonstrations
and/or Digirad roadshows (not for sale to customers). Segami shall deliver the
Demo Versions within *** days upon written request from Digirad.

                  3.3      AUDIT. Segami shall have the right to audit the
books, financial accounts and documents of Digirad *** in each calendar year for
which this contract is in force, to verify the number of copies of the Base
Software disseminated by Digirad. Segami shall employ an independent Certified
Public Accountant at its own cost and expense for such audit. Segami shall give
Digirad a minimum of *** days prior written notification of the audit. Digirad
shall not unreasonably withhold its cooperation in the audit.

         4.       INTERFACE DEVELOPMENT.

                  4.1      DEVELOPMENT. Segami agrees to undertake and complete
the code design, programming and testing of the Interface Development. Interface
Development shall be in accordance with the specifications on the attached
Exhibit B (the "Specifications") and the delivery schedule attached hereto as
Exhibit C (the "Delivery Schedule"). Segami shall be

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                  Page 2 of 10
<Page>

responsible for obtaining and maintaining operational status and approvals of
the Base Software and Interface Development (and any new versions or
improvements thereto) under FDA, CE and other regulatory authorities or
agencies. Segami agrees that its conduct in performing its obligations under
this Agreement shall conform in all material respects to all applicable laws and
regulations of the U.S. and foreign governments (and political subdivisions
thereof).

                  4.2      ACCEPTANCE. Digirad will, by written notice, accept
or reject any portion of the Interface Development delivered (individually, the
"Deliverable(s)") within *** days after receipt. Failure to give notice of
acceptance or rejection within that period will constitute acceptance. Digirad
may reject any Deliverable only if the Deliverable fails to meet the
Specifications or, at the fault or failing of that Deliverable alone, the
Product cannot operate in a commercially reasonable manner. If Digirad properly
rejects the Deliverable, Segami will correct the failures properly specified in
the rejection notice within *** days of the rejection notice. When it believes
that it has made the necessary corrections, Segami will again deliver the
Deliverable to Digirad and the acceptance/rejection/correction provisions above
shall be reapplied until the Deliverable is accepted; provided, however, that
upon the *** or any subsequent rejection or if the corrections are not made
within *** days of the initial rejection, Digirad may at its option terminate
this Agreement by immediate written notice unless the Deliverable is accepted
during the notice period.

         5.       COMPENSATION FOR INTERFACE DEVELOPMENT. Digirad shall make
payments to Segami in accordance with the Delivery Schedule. Each payment will
be in U.S. dollars from the United States and will be made no later than ***
days from the occurrence of the event specified in the Delivery Schedule for
which payment is due.

         6.       OWNERSHIP RIGHTS. As between the parties Segami shall retain
all right title and interest, including all patent, copyright, trade secret,
trademark, mask work or other rights, in the Base Software, or any other idea or
product conceived or reduced to form by Segami, its agents or assigns as of the
Effective Date. Digirad shall have all right, title and interest, in the
Interface Development. The parties hereby make any assignments necessary to
accomplish the foregoing ownership provisions.

         7.       SUPPORT/MAINTENANCE.

                  7.1      SUPPORT.  During the term of this Agreement:

                           (1)      Segami shall use its best efforts to respond
within *** days after receipt of written notice of verifiable defects, and
propose a plan for prompt and effective remedy, and shall provide general
guidance concerning the Base Software or Interface Development. Defects shall be
reported in writing via electronic mail or facsimile to Segami at the
telephone/email numbers provided by Segami to Digirad from time to time.

                           (2)      Segami shall inform Digirad promptly of any
changes in the Base Software or delivery schedules.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                  Page 3 of 10
<Page>

                           (3)      Subject to the other terms and conditions of
this Agreement, Segami shall use its reasonable best efforts to promptly fill
Digirad's orders for Keys. Promptly following the execution of this Agreement,
Segami shall place *** Keys in escrow. If Segami materially fails to provide a
sufficient number of Keys to Digirad for delivery of Products to end-users,
after *** days written notice to Segami, Digirad shall be entitled to receive
from escrow any or all of the Keys. If Segami fails to provide a sufficient
number of Keys to Digirad for delivery of Products to end-users, after *** days
written notice to Segami, Digirad shall be entitled to a fully executed purchase
order from Segami to the Key manufacturer ("Escrow Materials") authorizing the
Key manufacturer to provide directly to Digirad those Keys reasonably necessary,
in Digirad's sole discretion, for Digirad to sell and install Product. In
support of the foregoing and promptly after execution of this Agreement, Segami
will place in escrow (pursuant to the terms of an escrow agreement in form
mutually acceptable to the parties hereto) the Escrow Materials as they exist at
the date of the Agreement. Segami will update the escrow with any new or
modified Escrow Materials and Keys promptly as it becomes necessary and will
notify Digirad when it does so. *** ***

                           (4)      Segami agrees to provide *** standard
training *** for Digirad personnel. *** shall be given at Digirad's main office
on a schedule reasonably acceptable to Segami but commencing no later than ***
days after Digirad's written request. ***
                                      ***
***

                           (5)      Segami shall provide free technical support
to Digirad personnel up to *** during the first year, and *** per year after
that. This does not include time spent on developments set forth in Section 4 or
Section 7.1(1). Segami shall provide Digirad with all the user's documentation
in its possession.

                  7.2      MAINTENANCE RELEASES. In the exercise of its sole
discretion and from time to time, Segami may develop and make available
maintenance release for the Base Software at no cost to Digirad. Such
maintenance release shall be patches for the purpose of correcting any
deficiencies in the Base Software which may become apparent to Digirad and
Segami after successful delivery of the Interface Development.

                  7.3      ENHANCEMENTS/UPGRADES. In the exercise of its sole
discretion and from time to time, Segami may develop and make available for sale
through Digirad to end-users, and at an additional license fee to Segami, to be
negotiated in good faith by the Parties, substantially upgraded versions of the
Base Software which incorporate significant functional changes or additions, or
substantially improved performance.

         8.       CONFIDENTIALITY. Each party agrees that all code, inventions
algorithms, know-how and ideas and all other business, technical and financial
information they obtain from the other are confidential information and property
of the disclosing party ("Confidential Information"). Each party shall use
Confidential Information of the other party which is disclosed to it only for
the purposes of this Agreement and shall not disclose such Confidential

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                  Page 4 of 10
<Page>

Information to-any third party, without the other party's prior written consent,
other than to Segami's subcontractors, subdistributors and employees on a
need-to-know basis. Each party agrees to take measures to protect the
confidentiality of the other party's Confidential Information that, in the
aggregate, are no less protective than those measures it uses to protect the
confidentiality of its own Confidential Information, but at a minimum, each
party shall take reasonable steps to advise their employees, subcontractors and
subdistributors of the confidential nature of the Confidential Information and
of the prohibitions on copying or revealing such Confidential Information
contained herein. The parties each agree to require that the other party's
Confidential Information be kept in a reasonably secure location.
Notwithstanding anything to the contrary contained in this Agreement neither
party shall be obligated to treat as confidential, or otherwise be subject to
the restrictions on use, disclosure or treatment contained in this Agreement for
any information disclosed by the other party (the "Disclosing party") which: (1)
is rightfully known to the recipient prior to its disclosure by the Disclosing
Party; (2) is generally known or easily ascertainable by non-parties of ordinary
skill in computer process design or programming or in the business of the
client; (3) is released by the Disclosing Party to any other person, firm or
entity (including governmental agencies or bureaus) without restrictions; (4) is
independently developed by the recipient without any reliance on Confidential
Information; or (5) is or later becomes publicly available without violation of
this Agreement or may be lawfully obtained by a party from a non-party. Neither
party will be liable to the other for inadvertent or accidental -disclosure of
Confidential Information if the disclosure occurs notwithstanding the party's
exercise of the same level of protection and care that such party customarily
uses in safeguarding its own confidential information.

         Notwithstanding the foregoing, all Confidential Information developed
by Segami, including but not limited to the Interface Development, in connection
with this Agreement shall be deemed Confidential Information of Digirad
disclosed by Digirad to Segami and exceptions (1) and (4) above will not be
applicable thereto.

         9.       EXPORT CONTROL. Each party hereby agrees to comply with all
export laws and restrictions and regulations of the Department of Commerce or
other United States or foreign agency or authority, and not to export, or allow
the export or re-export of any proprietary information or software or any copy
or direct product thereof in violation of any such restrictions, laws or
regulations.

         10.      TERMINATION

                  10.1     TERMINATION BY DIGIRAD. Digirad may terminate this
Agreement if Segami is in material breach of, or default under, this Agreement
and such breach or default is not cured within *** days after Digirad delivers
written notice of such breach or default to Segami.

                  10.2     TERMINATION BY SEGAMI. Segami may terminate this
Agreement if Digirad is in material breach of or default under, this Agreement
and such breach or default is not cured within *** days after written notice to
Digirad. A material breach of and default

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                  Page 5 of 10
<Page>

under, this Agreement by Digirad shall include, without limitation, the
occurrence of the failure of Digirad to pay any License Fee when due.

                  10.3     SURVIVAL. Sections 5-15 of this Agreement, any
accrued rights to payment, any licenses granted in this Agreement that are
expressly perpetual and any remedies for breach of this Agreement shall survive
termination.

         11.      LIMITATION OF LIABILITY.

                  (a)      Except under Section 8 and the indemnity provisions
of Section 12, neither party nor its affiliates shall, under any circumstances,
be liable to the other party or its affiliates for any claim based upon any
third party claim or for consequential, incidental, indirect, punitive,
exemplary or special damages of any nature whatsoever, or for any damages
arising out of or in connection with any malfunctions, delays, loss of data,
loss of profit, interruption of service or loss of business or anticipatory
profits, even if a party or its affiliates have been apprised of the likelihood
of such damages occurring.

                  (b)      ***
                           ***
                           ***

         12.      INDEMNIFICATION

                  (a)      The parties each agree to indemnify, defend and hold
harmless the other from and against any and all amounts, including legal fees
and other out-of-pocket expenses, payable under any judgment, verdict, court
order or settlement for death or bodily injury or the damage to or loss or
destruction of any real or tangible personal property to the extent arising out
of the indemnitor's negligence, gross negligence, or willful misconduct in the
performance of this Agreement.

                  (b)      Segami agrees to indemnify, defend and hold harmless
Digirad, its distributors and end-users from and against any and all amounts,
including legal fees and other out-of-pocket expenses, payable under any
judgment, verdict, court order or settlement to the extent resulting from any
third party allegation that the Base Software or the work performed by Segami
under this Agreement infringes such third party's intellectual property rights,
including, without limitation, patent, copyright or trade secret. Should
Digirad's use of work performed by Segami be determined to have infringed, or if
in Segami's and Digirad's reasonable judgment such use is likely to be
infringing, *** *** ***

                  (c)      Digirad agrees to indemnify, defend and hold harmless
Segami from and against any and all amounts payable under any judgment, verdict,
court order or settlement to the extent resulting from any affiliated third
party allegation that the work performed by Segami under this Agreement
infringes such third party's intellectual property rights to the extent
attributable to software, hardware, data, knowledge or services provided by
Digirad.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                  Page 6 of 10
<Page>

                  (d)      The indemnities in this paragraph are contingent
upon: (1) the indemnified party promptly notifying the indemnifying party in
writing of any claim which may give rise to a claim for indemnification
hereunder; (2) the indemnifying party being allowed to control the defense and
settlement of such claim; and (3) the indemnified party cooperating with all
reasonable requests of the indemnifying party (at the indemnifying party'
expense) in defending or settling such claim. The indemnified party shall have
the right, at its option and expense, to participate in the defense of any
action, suitor proceeding relating to such a claim through a counsel of its own
choosing.

         13.      WARRANTIES. Segami warrants that it has and will obtain
agreements with its employees and contractors sufficient to allow it to provide
Digirad with the assignments and licenses to intellectual property rights
contemplated in this Agreement. Segami also warrants that the Base Software and
Interface Development and any part thereof shall meet the Specifications, and
perform in a commercially reasonable manner until the later of (i) *** years
from the final date of delivery on the Delivery Schedule and (ii) with respect
to each product containing the Base Software and/or Interface Development, ***
year from the date of installation of such product by Digirad or its distributor
to an end-user. If Digirad finds that the Products, or part thereof fail to meet
the above warranty, Segami shall, at its option, immediately repair or replace
the Base Software and/or Interface Development or part thereof at its costs and
expenses without prejudice to any other rights and remedies of Digirad under
this Agreement or applicable law. If a Deliverable is rejected, the warranty
will extend accordingly from any adjusted final delivery date. Except for
Section 14, notwithstanding anything to the contrary contained in this
Agreement, Segami makes no other warranties, express or implied, or whether
arising by operation of law, course of performance or dealing, custom, usage in
the trade or profession or otherwise including without limitation implied
warranties of merchantability and fitness for a particular purpose.

         14.      MILLENNIUM WARRANTY.

                  14.1     GENERAL, Other sections of this Agreement
notwithstanding, Segami represents and warrants that for a period of four (4)
years after the Effective Date, the Base Software and the Interface Development
will be able to accurately: (a) process any date-roll event with no adverse
impact on the functionality of the software including without limitation, the
producing of error(s) or abnormal interruption; (b) process date-data
calculations including, without limitation, computation, comparisons,
sequencing, sorts and extracts and return and display date-data in a consistent
manner regardless of the dates used in such date-data whether before, on,
during, or after January 1, 2000; (c) process any date-data computations that
can be expected from the software if used for its intended purpose, regardless
of the date in time on which the processes are actually performed and regardless
of the date-data input, whether before, on, during or after January 1, 2000; (d)
exchange date-data related information with other hardware, firmware or software
with which it interacts, provided that the interacting hardware, firmware or
software is itself capable of exchanging accurate date-data; (e) accept and
respond to four-digit year-date input in a manner that resolves any ambiguities
as to the century in a defined predetermined and appropriate manner; and (f)
store and display date-data in ways that are unambiguous as to the determination
of the century. No date-data shall cause such software to

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                  Page 7 of 10
<Page>

perform an abnormally ending routine or function within the processes or
generate incorrect values or invalid results. For purposes of the foregoing, a
date-rollover event is defined as any transaction between one calendar year and
the following calendar year including, without limitation, any time, date and
day-of-the-week progressions and any regularly scheduled leap events. Date-data
is defined as any data, formula, algorithm, process, input or output, which
includes, calculates or represents a date, day or time, a reference to a date,
day or time, or a representation of a date, day or time.

                  14.2     SPECIAL REMEDIES. In the event of any breach of the
warranties and covenants contained in this section, provided that such breach is
not cured by Segami within *** days following receipt of written notice of such
breach, in addition to other rights and remedies that may be available to
Digirad under this Agreement, Segami shall be responsible for: (a) any costs of
repairing, replacing and/or correcting the affected software; and (b) cover and
other similar damages that are incurred by Digirad as a result of Segami's
breach of this warranty.

         15.      MISCELLANEOUS

                  15.1     BINDING NATURE. This Agreement shall be binding upon
and shall inure to the benefit of the parties to this Agreement and their
respective successors and permitted assigns. Segami shall not have any right or
ability to assign, transfer, or sublicense any obligations or benefit under this
Agreement without the written consent of Digirad, except that Segami may assign
and transfer this Agreement and its rights and obligations hereunder to any
third party who succeeds to substantially all its business or assets.

                  15.2     ENTIRE AGREEMENT. This Agreement constitutes the
entire agreement between the parties and there are no representations,
warranties, covenants, or obligations except as set forth in this Agreement.
This Agreement supersedes all prior or contemporaneous agreements
understandings, negotiations and discussions, written or oral, of the parties to
this Agreement, relating to any transaction contemplated by this Agreement.

                  15.3     SEVERABILITY. Each provision of this Agreement shall
be considered separable and if for any reason any provision or provisions in
this Agreement are determined to be invalid arid contrary to any existing or
future law, that invalidity shall not impair the operation of this Agreement or
affect those portions of this Agreement which are valid.

                  15.4     ARBITRATION. If any dispute or controversy arises
among the parties to this Agreement concerning any provision of this Agreement,
that dispute or controversy shall be submitted for resolution to a board of
arbitration in *** *** *** Such arbitration shall be conducted pursuant to the
rules of the American Arbitration Association (the "AAA") or other governing
rules and *** *** ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                  Page 8 of 10
<Page>

                  15.5     NO AGENCY. This Agreement shall not be deemed to
constitute the parties hereto as partners, joint venturers, nor shall either
patty hereto be deemed to be an agent of any nature, kind and description
whatsoever of the other.

                  15.6     JURISDICTION AND VENUE. This Agreement shall be
governed, enforced, performed and construed in accordance with the laws of the
State of *** *** Subject to the provisions of Section 15.4 hereof each of the
parties hereto hereby submits to the exclusive jurisdiction of the state and/or
federal courts located within the State of *** for any suit, hearing or other
legal proceeding of every nature, kind and description whatsoever in the event
of any dispute or controversy arising hereunder or relating hereto, or in the
event any ruling, finding or other legal determination is required or desired
hereunder.

                  15.7     ATTORNEYS FEES. In the event that legal proceedings
are commenced in connection with this Agreement or the transactions contemplated
hereby, the party or parties *** *** ***

                  15.8     AMBIGUITY. The parties acknowledge that each party
and its respective counsel have reviewed and revised this Agreement and that the
normal rule of construction to the effect that any ambiguities are to be
resolved against the drafting party shall not be employed in the interpretation
of this Agreement or any amendments or exhibits, or schedules hereto.

                  15.9     EXHIBITS. The exhibits attached hereto and each
certificate, schedule, list summary or other document provided or delivered
pursuant to this Agreement or in connection with the transactions contemplated
hereby are incorporated herein by this reference and made a part hereof.

                  15.10    COUNTERPARTS. Provided that all parties hereto
execute a copy of this Agreement, this Agreement may be executed in
counterparts, each of which shall he deemed an original and all of which
together shall constitute one and the same instrument. Executed copies of this
Agreement may be delivered by facsimile transmission or other comparable
electronic means.

                  15.11    VOLUNTARY AGREEMENT. The parties hereto represent
that they have carefully read the foregoing Agreement, understood its terms,
consulted with an attorney of their choice, and voluntarily signed the same as
their own free act with the intent to be legally bound thereby. The terms of
this Agreement are contractual and not a mere recital.

                  15.12    FORCE MAJEURE. Neither party shall be liable to the
other for its failure to perform any of its obligations under this Agreement
during any period in which such performance is delayed due to circumstances
beyond its control, including acts of God or public authorities, was and war
measures, civil unrest, natural disasters or delays in transportation, delivery
or supply.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                  Page 9 of 10
<Page>

                  15.13    NOTICE. All notices under this Agreement shall be in
writing and shall be deemed given when personally delivered or three days after
being sent prepaid certified or registered United States mail to the address of
the party to be noticed as set forth below or such other addresses as such party
last provided to the other by notice:

                           Digirad:         Digirad Corporation
                                            9350 Trade Place
                                            San Diego CA 92126
                                            Attn: President and COO

                           Segami:          Segami Corporation
                                            12624 Golden Oak Drive
                                            Ellicott City MD 21042
                                            Attn: Philippe Briandet Ph.D.

                           Copy to:         Christopher S. Young, Esq.
                                            3440 Ellicott Center Drive
                                            Ste. 203
                                            Ellicott City MD 21043

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed
under seal as of the date first above written.

ATTEST:                                        Digirad Corporation

By:      /s/ ILLEGIBLE                       By:     /s/ Scott Huennekens
   -------------------------------              --------------------------------
Title:        Controller           (SEAL)    Title:    President & COO
      ----------------------------                 -----------------------------

                                             Segami Corporation

By:         /s/ ILLEGIBLE       (Secretary)  By:        /s/ ILLEGIBLE
   -------------------------------                ------------------------------
Title:                             (SEAL)    Title:      President
      ----------------------------                 -----------------------------

                                  Page 10 of 10
<Page>

                                    EXHIBIT A
                                PRICING SCHEDULE

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                      A-1
<Page>

                                    EXHIBIT B

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

--------------------------------------------------------------------------------
Information contained in this document is proprietary to DIGIRAD Corporation and
should not be released outside of the company without written permission of the
company.
--------------------------------------------------------------------------------

                                      B-1
<Page>

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

--------------------------------------------------------------------------------
Information contained in this document is proprietary to DIGIRAD Corporation and
should not be released outside of the company without written permission of the
company.
--------------------------------------------------------------------------------

                                      B-2
<Page>

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

--------------------------------------------------------------------------------
Information contained in this document is proprietary to DIGIRAD Corporation and
should not be released outside of the company without written permission of the
company.
--------------------------------------------------------------------------------

                                      B-3
<Page>

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

--------------------------------------------------------------------------------
Information contained in this document is proprietary to DIGIRAD Corporation and
should not be released outside of the company without written permission of the
company.
--------------------------------------------------------------------------------

                                      B-4
<Page>

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

--------------------------------------------------------------------------------
Information contained in this document is proprietary to DIGIRAD Corporation and
should not be released outside of the company without written permission of the
company.
--------------------------------------------------------------------------------

                                      B-5
<Page>

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

--------------------------------------------------------------------------------
Information contained in this document is proprietary to DIGIRAD Corporation and
should not be released outside of the company without written permission of the
company.
--------------------------------------------------------------------------------

                                      B-6
<Page>

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

--------------------------------------------------------------------------------
Information contained in this document is proprietary to DIGIRAD Corporation and
should not be released outside of the company without written permission of the
company.
--------------------------------------------------------------------------------

                                      B-7
<Page>

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

--------------------------------------------------------------------------------
Information contained in this document is proprietary to DIGIRAD Corporation and
should not be released outside of the company without written permission of the
company.
--------------------------------------------------------------------------------

                                      B-8
<Page>

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

--------------------------------------------------------------------------------
Information contained in this document is proprietary to DIGIRAD Corporation and
should not be released outside of the company without written permission of the
company.
--------------------------------------------------------------------------------

                                      B-9
<Page>

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

--------------------------------------------------------------------------------
Information contained in this document is proprietary to DIGIRAD Corporation and
should not be released outside of the company without written permission of the
company.
--------------------------------------------------------------------------------

                                      B-10
<Page>

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

--------------------------------------------------------------------------------
Information contained in this document is proprietary to DIGIRAD Corporation and
should not be released outside of the company without written permission of the
company.
--------------------------------------------------------------------------------

                                      B-11
<Page>

                                    EXHIBIT C
                                DELIVERY SCHEDULE

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                      C-1
<Page>

                                    EXHIBIT D
                             SEGAMI'S BASE SOFTWARE

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission.

                                      D-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}]]